This is a working overview of rodent models, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
| Property | Value | Notes |
|---|---|---|
| Molar mass | Approximately 1419.5 g/mol | Calculated from the reported 15-residue sequence |
| Molecular formula | C62H98N16O22 | Based on the same sequence |
| Appearance | White to off-white powder | Typical of a lyophilized preparation |
| Solubility class | Freely soluble in water | Also dissolves in saline solutions |
| Typical storage temperature | Minus 20 degrees Celsius, dry | Refrigeration advised after reconstitution |
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
At least 90% of smallpox cases among unvaccinated persons were of the ordinary type. In this form of the disease, by the second day of the rash the macules had become raised papules. By the third or fourth day, the papules had filled with an opalescent fluid to become vesicles. This fluid became opaque and turbid within 24–48 hours, resulting in pustules. By the sixth or seventh day, all the skin lesions had become pustules. Between seven and ten days the pustules had matured and reached their maximum size. The pustules were sharply raised, typically round, tense, and firm to the touch. The pustules were deeply embedded in the dermis, giving them the feel of a small bead in the skin. Fluid slowly leaked from the pustules, and by the end of the second week, the pustules had deflated and began to dry up, forming crusts or scabs. By day 16–20 scabs had formed over all of the lesions, which had started to flake off, leaving depigmented scars. Ordinary smallpox generally produced a discrete rash, in which the pustules stood out on the skin separately. The distribution of the rash was most dense on the face, denser on the extremities than on the trunk, and denser on the distal parts of the extremities than on the proximal. The palms of the hands and soles of the feet were involved in most cases.
Mexico's tequila protection interests were prominent during the Chinese accession negotiations to the World Trade Organization. In accordance with WTO accession regulations, in order to gain considerations for WTO membership, China had to sign bilateral agreements with all existing members, including Mexico. Since China has a climatic condition suitable for blue agave plants, Mexico was worried about rival pseudo tequilas from China. The Mexican authorities took the opportunity of the bilateral negotiations with China to ensure that the latter accepted tequila as a geographically indicated product.
=== Horse racing === In June 2015, Monster agreed to a sponsorship deal with Zayat Stables to sponsor the race horse American Pharoah, rumored to be the largest single-horse advertising sponsorship to-date. The deal allows the product's logo to be used on the horse sheets, on jockey Victor Espinoza's shirt and boots, as well as caps and other gear worn by people around the horse.
On 8 April 2026, the United States and Iran agreed to a two-week ceasefire in the 2026 Iran war, mediated by Pakistan. Iran had rejected the draft proposal for a 45-day two-phase ceasefire framework introduced on 5 April by Pakistan, instead proposing its own 10-point plan for a peace agreement. The proposal was developed as part of ongoing mediation efforts involving regional and international actors during the 2025–2026 negotiations. Since its declaration, the ceasefire was violated by both sides numerous times. On 21 April, US president Donald Trump extended the ceasefire indefinitely. On 8 July, the ceasefire deal collapsed after attacks by both sides. Low-intensity fighting between the US and Iran continued intermittently. Later, Trump decided to arrive at a more comprehensive ceasefire that would lead to an US–Iranian agreement. As a result, new ceasefire conditions were agreed upon on 12 June. On 17 June, the presidents of both countries signed the Islamabad Memorandum, a memorandum of understanding that formalized the process of ending the war and established a 60-day period to negotiate the final terms of a deal.
The supernatant contains a mitogenic factor, a mitosis promoting factor, that is characterized heat and trypsin sensitivity, both of which characterize it as a peptide. Treatment of Schwann cells with the collected supernatant shows that it is a mitogenic factor and thus plays an important role in the proliferation of Schwann cells. Macrophages are also involved in the secretion factors that promote nerve regeneration. Macrophages secrete not only interleukin-1, a cytokine that induces expression of nerve growth factor (NGF) in Schwann cells but also an interleukin-1 receptor antagonist (IL-1ra). Expression of IL-1ra in mice with transected sciatic nerves via implantation of a tube releasing IL-1ra showed the regrowth of fewer myelinated and unmyelinated axons. Macrophage secretion of interleukin-1 is involved in stimulation of nerve regeneration.
Sources: en.wikipedia.org
=== Off-label drugs === α2-Adrenergic receptor agonists (e.g., clonidine, tizanidine) Acetaminophen (paracetamol) Adenosine receptor antagonists (e.g., caffeine) Angiotensin-converting-enzyme inhibitors (ACE inhibitors) (e.g., lisinopril) Angiotensin receptor antagonists (e.g., candesartan, telmisartan) Antipsychotics and related (e.g., prochlorperazine, metoclopramide, haloperidol, promethazine, chlorpromazine) Anticonvulsants (e.g., valproic acid) Barbiturates (e.g., butalbital, proxibarbital) Beta blockers (β-adrenergic receptor antagonists) (e.g., propranolol, metoprolol, nadolol, timolol, atenolol) Calcium channel blockers (e.g., verapamil, nimodipine, nifedipine, diltiazem) Cannabinoids (cannabinoid receptor agonists) (e.g., cannabis, tetrahydrocannabinol (THC)) Corticosteroids (e.g., dexamethasone, prednisone) Ergoline monoamine receptor modulators (e.g., ergotamine, methylergometrine, methysergide, dihydroergocryptine, bromocriptine, lisuride) Estrogens (estrogen receptor agonists) (e.g., estradiol, ethinylestradiol) Gabapentinoids (α2δ subunit-containing volate-gated calcium channel ligands) (e.g., gabapentin, pregabalin) Melatonin Nonsteroidal anti-inflammatory drugs (NSAIDs; COX inhibitors) (e.g., ibuprofen, aspirin, naproxen, diclofenac, ketorolac, ketoprofen) Opioids (μ-opioid receptor agonists) (e.g., morphine, codeine, oxycodone, hydrocodone) Progestogens (progesterone receptor agonists) (e.g., progesterone, medroxyprogesterone acetate) Propofol Serotonergic psychedelics (e.g., psilocybin, lysergic acid diethylamide (LSD), dimethyltryptamine (DMT)) Serotonin receptor antagonists (e.g., methysergide, pizotifen, cyproheptadine) Sodium channel blockers (e.g., lidocaine) Tetracyclic antidepressants (TeCAs) (e.g., mianserin, mirtazapine) Tricyclic antidepressants (TCAs) (e.g., amitriptyline, nortriptyline, imipramine)
==== Binding RuBP ==== Carbamylation of the ε-amino group of Lys210 is stabilized by coordination with the Mg2+. This reaction involves binding of the carboxylate termini of Asp203 and Glu204 to the Mg2+ ion. The substrate RuBP binds Mg2+ displacing two of the three aquo ligands.
Aminoacyl-tRNA synthetase enzymes consume ATP in the attachment tRNA to amino acids, forming aminoacyl-tRNA complexes. Aminoacyl transferase binds AMP-amino acid to tRNA. The coupling reaction proceeds in two steps:
=== Modern accounts === Goldstein, Martin, and Inge F., (1993). The Refrigerator and the Universe. Harvard Univ. Press. A gentle introduction. Kroemer, Herbert; Kittel, Charles (1980). Thermal Physics (2nd ed.). W. H. Freeman Company. ISBN 978-0-7167-1088-2. Nolan, Peter J. (1996). Fundamentals of College Physics, 2nd ed. William C. Brown Publishers. Oxtoby & Nachtrieb (1996). Principles of Modern Chemistry, 3rd ed. Saunders College Publishing. Papineau, D. (2002). Thinking about Consciousness. Oxford: Oxford University Press. Serway, Raymond A.; Jewett, John W. (2004). Physics for Scientists and Engineers (6th ed.). Brooks/Cole. ISBN 978-0-534-40842-8. Stenger, Victor J. (2000). Timeless Reality. Prometheus Books. Especially chpt. 12. Nontechnical. Tipler, Paul (2004). Physics for Scientists and Engineers: Mechanics, Oscillations and Waves, Thermodynamics (5th ed.). W. H. Freeman. ISBN 978-0-7167-0809-4. Lanczos, Cornelius (1970). The Variational Principles of Mechanics. Toronto: University of Toronto Press. ISBN 978-0-8020-1743-7.
During cancer T cell exhaustion plays a role in tumor protection. According to research some cancer-associated cells as well as tumor cells themselves can actively induce T cell exhaustion at the site of tumor. T cell exhaustion can also play a role in cancer relapses as was shown on leukemia. Some studies have suggested that it is possible to predict relapse of leukemia based on expression of inhibitory receptors PD-1 and TIM-3 by T cells. Many experiments and clinical trials have focused on immune checkpoint blockers in cancer therapy, with some of these approved as valid therapies that are now in clinical use. Inhibitory receptors targeted by those medical procedures are vital in T cell exhaustion and blocking them can reverse these changes.
Sources: en.wikipedia.org
It does not occur in the form that is supplied commercially. Its sequence matches a fragment of a larger gastric protein, and the research material is produced synthetically in a laboratory. The fragment described in the early literature is generally the same synthetic pentadecapeptide.
It marks the position of the sequence inside the original protein. The label traces back to early work fractionating gastric juice and describing a body protection compound. The figure does not refer to molecular weight or to the count of amino acids.
No. The sequence has no cysteine residues, so disulfide bridges cannot form. That feature makes it easier to handle than many small proteins that depend on multiple cysteines for structure.
The standard approach is reverse-phase high-performance liquid chromatography, reported as a percentage of total peak area. Because that figure alone says little about the nature of the impurities, the accompanying chromatogram is normally the more useful document for judging a batch.